Powered 500 · 2026POWEREDS. 241 of 500
Mazumdar took Bicara through one of biotech's largest IPOs of 2024 while advancing ficerafusp alfa — a single molecule combining EGFR targeting and TGF-beta inhibition — into pivotal trials for head and neck cancer, positioning the company at the front of bifunctional antibody oncology.
Claire Mazumdar is CEO of Bicara Therapeutics, a clinical-stage biotechnology company developing bifunctional antibody cancer therapies.
Bicara's lead program, ficerafusp alfa, combines EGFR targeting with TGF-beta trap functionality in a single molecule and has advanced into pivotal clinical development for head and neck squamous cell carcinoma. Under her leadership Bicara completed one of 2024's largest biotech IPOs, and she was named a 2025 EY Entrepreneur of the Year New England Award winner.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
